Chronic Kidney Disease
The Pharmacy Times® Chronic Kidney Disease resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Todd Brothers, PharmD, BCCCP, BCPS clinical assistant professor, University of Rhode Island, discusses the role of pharmacists in assessing patients for hyperkalemia and in managing those with a chronic condition. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.
Patients with HIV who are diagnosed with chronic kidney disease have a higher burden of serious clinical events.
Jaclyn Harth, PharmD, clinical assistant professor, Fairleigh Dickinson School of Pharmacy, discusses the role of the health system pharmacist for patients with chronic hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.
A recent study showed that effective lifestyle behavioral changes for patients with chronic kidney disease frequently involved education, goal setting, feedback, monitoring, and social support.
A retrospective cohort study was the second largest evaluation to date of sodium polystyrene sulphonate use and safety in patients with chronic kidney disease.
A study using genomics and proteomics identified new subtypes of clear cell renal cell carcinoma based on tumor microenvironment signatures.
More men than women initiate kidney replacement therapy despite a higher prevalence of chronic kidney disease seen in women.
A study published in the Clinical Journal of American Society of Nephrology found that a healthy dietary pattern may prevent chronic kidney disease (CKD) and albuminuria.
A recent study suggests that hyperkalemia and uncomplicated hyperglycemia in patients treated in the emergency department is commonly caused by iatrogenesis.
No Significant Difference with Vitamin D3, Omega-3 Fatty Acids in Patients with Chronic Kidney Disease
Neither vitamin D nor omega-3 fatty acid supplementation were found to significantly inhibit changes in serum creatinine and cystatin C decline over 5 years among adults with type 2 diabetes.
Phase 3 Trial Shows Positive Efficacy, No Increased Cardiovascular Risk for Hemoglobin-Increasing Drug
Roxadustat for the treatment of patients with anemia from chronic kidney disease was shown to have positive efficacy and no increased cardiovascular risk in patients dependent and not dependent on dialysis.
The oral therapy is indicated to act as both a monotherapy and a combination therapy to improve glycemic control. It is also indicated to prevent cardiovascular and renal death in patients with CKD.